Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Clinical Study Evaluating Allogeneic iPSC-derived Pancreatic Islet Cells (CRG-002) for the Treatment of Diabetic Patients With Hypoglycemia Unawareness or Severe Hypoglycemic Events

NCT07503028 is registered in ClinicalTrials.gov with Celregen Therapeutics as lead sponsor.

NCT NCT07503028
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07503028 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Clinical Study Evaluating Allogeneic iPSC-derived Pancreatic Islet Cells (CRG-002) for the Treatment of Diabetic Patients With Hypoglycemia Unawareness or Severe Hypoglycemic Events
Lead sponsor
Celregen Therapeutics
Phase
Phase 1
Overall status
Enrolling by invitation
Start date
October 17, 2025
Completion date
January 18, 2028
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatogenic diabetes mellitus, t1dm - type 1 diabetes mellitus